SAB Biotherapeutics, Inc. (SABSW) community

SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 4/30

$0.01+0.00 (+33.33%)

Close on Oct 20, 2026Market cap $304.80MP/E –Yield –

Community

Notes and questions about SAB Biotherapeutics from other investors

No posts about SABSW yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in SAB Biotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5.67 reverse split on Mar 29, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SABSW.

Compare: SABSW vs SCNI · SABSW vs IMA · SABSW vs PLUR · SABSW vs INBX · SABSW vs PROK

Revenue growth-100.0% · median 15.6%

Company	Revenue	Growth
PLUR	$1.02M	-24.0%
PROK	$818.00K	+55.2%
SABSW	$0	-100.0%
SCNI	–	–
IMA	–	–
INBX	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 86
Auditor: EisnerAmper L.L.P.
SEC CIK: 1833214

Advertisement
300 × 250